Clinical Trials Browser

Interventional × trilaciclib × Thoracic × Clear all

NCT06370416 2026-01-28

the Prevention of Bone Marrow Suppression Caused by Chemotherapy in Advanced NSCLC With Trilaciclib

Phase 2 Enrolling by invitation

Carcinoma, Non-Small-Cell Lung

NCT02514447 2025-09-25

Trilaciclib (G1T28) in Patients With Previously Treated Extensive Stage SCLC Receiving Topotecan Chemotherapy

Phase 1/2 Completed

123 enrolled 46 charts

Small Cell Lung Carcinoma

NCT03041311 2025-09-25

Carboplatin, Etoposide, and Atezolizumab With or Without Trilaciclib (G1T28), a CDK4/6 Inhibitor, in Extensive-Stage SCLC

Phase 2 Completed

107 enrolled 42 charts

Small Cell Lung Carcinoma

NCT05874401 2025-09-04

Trilaciclib vs Placebo in Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC) Receiving Topotecan

Phase 4 Recruiting

Small Cell Lung Carcinoma

NCT05578326 2025-07-08

Study of Trilaciclib and Lurbinectidin

Phase 2 Recruiting

Lung Neoplasms, Neutropenia, Small Cell Lung Carcinoma

NCT06992739 2025-05-28

PROTECT-2

Phase 2 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT04902885 2024-07-10

Phase 3 Study Evaluating Efficacy, Safety and Pharmacokinetics of Trilaciclib In Small Cell Lung Cancer Patients

Phase 3 Completed

95 enrolled 27 charts

Small Cell Lung Carcinoma

NCT06328049 2024-03-25

A Study of Trilaciclib Combined With Chemotherapy in the Treatment of NSCLC

Phase 2 Recruiting

NSCLC

NCT06297811 2024-03-07

Myeloprotection With Trilaciclib in Pan-cancer Population

Phase 2 Not yet recruiting

BreastGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Endometrial Neoplasms

NCT05071703 2023-10-06

Evaluation of TRILACICLIB in Chinese Patients With Extensive-stage Small Cell Lung Cancer (ES-SCLC) for Chemotherapy-induced Myelosuppression, Antitumor Effects of Combination Regimens, and Safety in a Real-world Study

Phase 4 Completed

Small Cell Lung Carcinoma

NCT05900921 2023-06-13

Trilaciclib Prior to Chemotherapy Plus Tislelizumab as 1L Treatment for Advanced Squamous Non-Small-Cell Lung Cancer

Phase 2 Unknown

Advanced Squamous Non-Small-Cell Lung Cancer

NCT04863248 2023-04-14

PRESERVE 4

Phase 2 Terminated

10 enrolled 14 charts

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasm Metastasis

NCT02499770 2020-08-21

Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Etoposide and Carboplatin in Extensive Stage Small Cell Lung Cancer (SCLC)

Phase 1/2 Completed

122 enrolled 62 charts

Small Cell Lung Carcinoma